Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.172 - Parallel Trajectories of Lung Function and Allergic Sensitization in Childhood Asthma: A 7-Year Prospective Study
D1.180 - Hidden fragility behind optimal ACT score: identifying silent-risk phenotypes through clinical-biological dissociation
D1.182 - Relationship between eHealth Literacy and Medication Adherence in Patients with Asthma: The Mediating Role of Self-Efficacy
D1.171 - Real-World Exacerbation Outcomes After AIR Therapy Rescue Implementation: Toward a SABA-Free Era
D1.173 - Sputum Tryptase Identifies Airway Mast Cell Activation Across Asthma Phenotypes
D1.174 - Framing ADAM17 alterations across bronchial, sputum and nasal sites in asthma and controls
D1.175 - Clinical Phenotypes of Difficult-to-treat and Mild Asthma Defined by Cluster Analysis
D1.176 - Prognostic Evaluation of the Allergic March in Patients with Atopic Dermatitis
D1.177 - Turkish Validity and Reliability of the Medication Adherence Report Scale for Asthma (MARS-A) in Adolescents with Asthma
D1.178 - Real-World Comparison of Inhaled Corticosteroid Monotherapy versus Fixed-Dose Inhaled Corticosteroid–Long-Acting Beta-2 Agonist Combinations in Children Aged 6–11 Years with Persistent Asthma
D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children
D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download